Galapagos NV

Research Galapagos NV (GLPG) on Bullrun: market cap USD 1.83B, P/E 4.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerGLPG
• ExchangeNASDAQ
• CountryBelgium
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.83B
• P/E4.6
• Financial periodQ1 2026
• RevenueUSD 6.48M
• Net incomeUSD 14.49M
• Free cash flow-USD 82.87M
• Gross margin26.0%

Valuation Snapshot

latest market cap is USD 1.83B; P/E is 4.6.

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma;

Frequently asked questions

What is Galapagos NV's market cap?

Galapagos NV's market capitalization is USD 1.83B.

What is Galapagos NV's P/E ratio?

Galapagos NV's price-to-earnings (P/E) ratio is 4.6.

What does Galapagos NV do?

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus;